13.09
-0.68%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Yantai Dongcheng Biochemicals Co
Its shares trade on Shenzhen under the ticker 002675.SZ. It has been listed since 25 May 2012. In the fiscal year to 31 December 2025, it reported revenue of CN¥2.72bn and net income of CN¥195.6m. At that date it held total assets of CN¥9.26bn and shareholders' equity of CN¥4.35bn.
Yantai Dongcheng Biochemicals Co., Ltd. engages in the research, development, production and sales of heparin sodium bulk drug and chondroitin sulfate. The company is headquartered in Yantai, Shandong. The company went IPO on 2012-05-25. The Company’s main products are categorized into active pharmaceutical ingredients (APIs), nuclear medicines, chemical drugs and traditional Chinese medicines, which include heparin sodium APIs, chondroitin sulfate, preparation products, radionuclide drugs and others. The firm distributes its products in domestic market and to overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 25 May 2012
- Employees
- 2,174
- Website
- dcb-group.com ↗
Leadership
Pay as last reported
- Mr. Shouyi YouChairman of the Board, since 2007CN¥1.8m
- Ms. Chunping ZhuChief Financial OfficerCN¥894,500
- Mr. Zhigang LuoGeneral Manager, Director, since 2018CN¥2.0m
- Mr. Xiaojie LiuDeputy General Manager, Secretary of the Board, Director, since 2018CN¥1.5m
- Ms. Sai YouDeputy General Manager, Director, since 2022CN¥505,800
- Mr. Chunxiang LuDeputy General ManagerCN¥439,800
- Ms. Jing SunDeputy General ManagerCN¥1.7m
- Mr. Xiaofeng NiuDirector
- Mr. Hongtao SunStaff Elected Director
- Mr. Fang LiIndependent DirectorCN¥70,000
- Mr. Dayong ZhaoIndependent DirectorCN¥70,000
- Mr. Rui ZhouIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Yantai Dongcheng Biochemicals employs 2174 full-time staff members for operations.
- The company produces heparin sodium bulk drugs and chondroitin sulfate APIs.
- Products include nuclear medicines and traditional Chinese medicines for diverse markets.
Weaknesses
- The firm relies on domestic market distribution for its product sales.
- Chondroitin sulfate is a single key API product line offered.
- Overseas market presence is not detailed in the current business description.
Opportunities
- Expanding overseas market distribution for heparin sodium APIs could increase revenue.
- Growing demand for nuclear medicines offers potential growth in the sector.
- Traditional Chinese medicines provide additional product categories for international expansion.
Threats
- Dependence on domestic market distribution limits immediate global revenue potential.
- Regulatory changes in the Health Care sector may impact API production.
- Competition in the biotechnology industry could pressure pricing for chondroitin sulfate.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.